Compare Cassava Sciences Inc (FLNA) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs KKR & Co Inc — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while KKR & Co Inc trades at $92.49 (market cap $80.39B). The key difference: KKR & Co Inc is far larger — about 2040.4× Cassava Sciences Inc's market cap, and KKR & Co Inc pays a 0.87% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and KKR & Co Inc for 67 Days on average.
| FLNA | KKR | |
|---|---|---|
Market Cap | $39.40M | $80.39B |
Volume | 759,018 | 6,517,705 |
Sector | Health | Financials |
52-Week High | $4.64 | $142.75 |
52-Week Low | $0.68 | $83.88 |
Typical Hold Time | 37 Days | 67 Days |
Enterprise Value | -$43.28M | $2.95B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
KKR trades at $92.48, up 3.13% today, showing strong momentum after recent earnings beats. The stock faces bearish technical signals but maintains solid fundamentals with $19.21B revenue and $2.37B net income for 2025. Recent business developments include strategic joint ventures and asset sales, while analyst consensus remains overwhelmingly bullish with an average price target of $123.30.
KKR presents a compelling investment opportunity with strong earnings momentum and institutional support, though technical indicators suggest near-term caution. The company's diversified investment portfolio and active deal flow provide growth catalysts, balanced by market volatility risks and the cyclical nature of private equity returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
